7 In our study, amisulpride augmentation was associated with a slightly greater chance of improvement to a criterion level of overall symptom reduction within 12 weeks and a modest improvement in negative symptoms, but these observed differences failed to reach statistical significance.
← all excerpts
Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial.
1
—
—